270 related articles for article (PubMed ID: 30173579)
1. Overview of intranasally delivered peptides: key considerations for pharmaceutical development.
Al Bakri W; Donovan MD; Cueto M; Wu Y; Orekie C; Yang Z
Expert Opin Drug Deliv; 2018 Oct; 15(10):991-1005. PubMed ID: 30173579
[TBL] [Abstract][Full Text] [Related]
2. Essential considerations towards development of effective nasal antibiotic formulation: features, strategies, and future directions.
Mardikasari SA; Katona G; Sipos B; Csóka I
Expert Opin Drug Deliv; 2024 Apr; 21(4):611-625. PubMed ID: 38588551
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules.
Fortuna A; Alves G; Serralheiro A; Sousa J; Falcão A
Eur J Pharm Biopharm; 2014 Sep; 88(1):8-27. PubMed ID: 24681294
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and physiological considerations for efficient nose-to-brain targeting.
Bahadur S; Pathak K
Expert Opin Drug Deliv; 2012 Jan; 9(1):19-31. PubMed ID: 22171740
[TBL] [Abstract][Full Text] [Related]
5. Drug development of intranasally delivered peptides.
Campbell C; Morimoto BH; Nenciu D; Fox AW
Ther Deliv; 2012 Apr; 3(4):557-68. PubMed ID: 22834082
[TBL] [Abstract][Full Text] [Related]
6. Intranasal drug delivery: opportunities and toxicologic challenges during drug development.
Keller LA; Merkel O; Popp A
Drug Deliv Transl Res; 2022 Apr; 12(4):735-757. PubMed ID: 33491126
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration.
Mathias NR; Hussain MA
J Pharm Sci; 2010 Jan; 99(1):1-20. PubMed ID: 19499570
[TBL] [Abstract][Full Text] [Related]
8. Characterizing regional drug delivery within the nasal airways.
Chen J; Finlay WH; Vehring R; Martin AR
Expert Opin Drug Deliv; 2024 Apr; 21(4):537-551. PubMed ID: 38568159
[TBL] [Abstract][Full Text] [Related]
9. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery.
Singh RM; Kumar A; Pathak K
Expert Opin Drug Deliv; 2013 Jan; 10(1):115-30. PubMed ID: 23199072
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for Intranasal Delivery to Improve Brain Uptake.
Patel AA; Patel RJ; Patel SR
Curr Drug Deliv; 2018; 15(4):461-469. PubMed ID: 29034836
[TBL] [Abstract][Full Text] [Related]
11. Intravail: highly effective intranasal delivery of peptide and protein drugs.
Maggio ET
Expert Opin Drug Deliv; 2006 Jul; 3(4):529-39. PubMed ID: 16822227
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.
Chen SC; Eiting K; Cui K; Leonard AK; Morris D; Li CY; Farber K; Sileno AP; Houston ME; Johnson PH; Quay SC; Costantino HR
J Pharm Sci; 2006 Jun; 95(6):1364-71. PubMed ID: 16625659
[TBL] [Abstract][Full Text] [Related]
13. Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Shah B; Khunt D; Misra M; Padh H
Pharm Res; 2018 Jan; 35(1):8. PubMed ID: 29294189
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery to the nasal cavity: in vitro and in vivo assessment.
Newman SP; Pitcairn GR; Dalby RN
Crit Rev Ther Drug Carrier Syst; 2004; 21(1):21-66. PubMed ID: 15099184
[TBL] [Abstract][Full Text] [Related]
15. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review.
Ditzinger F; Price DJ; Ilie AR; Köhl NJ; Jankovic S; Tsakiridou G; Aleandri S; Kalantzi L; Holm R; Nair A; Saal C; Griffin B; Kuentz M
J Pharm Pharmacol; 2019 Apr; 71(4):464-482. PubMed ID: 30070363
[TBL] [Abstract][Full Text] [Related]
16. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.
Cherniakov I; Domb AJ; Hoffman A
Expert Opin Drug Deliv; 2015 Jul; 12(7):1121-33. PubMed ID: 25556987
[TBL] [Abstract][Full Text] [Related]
17. Nasal route: an alternative approach for antiemetic drug delivery.
Ozsoy Y; Güngör S
Expert Opin Drug Deliv; 2011 Nov; 8(11):1439-53. PubMed ID: 22004793
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.
Bak A; Leung D; Barrett SE; Forster S; Minnihan EC; Leithead AW; Cunningham J; Toussaint N; Crocker LS
AAPS J; 2015 Jan; 17(1):144-55. PubMed ID: 25398427
[TBL] [Abstract][Full Text] [Related]
19. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
Hu X; Yang FF; Liao YH
Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
